Nanoscope Therapeutics to Present at the 13th The Eye and the Chip World Research Congress

Nanoscope Therapeutics to Present at the 13th The Eye and the Chip World Research Congress

DALLAS, TX (October 9, 2023) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Dr. Arup Roy, and Michael Carlson will present at the 13th The Eye and The Chip World Research Congress taking place from October 8-10 in Southfield, Michigan. Details for the presentations are as follows:

Title: Development and Validation of the Multi-Luminance Y-Mobility Test (MLYMT)) for Assessment of Vision-Guided Mobility in Patients with Profound Vision Loss

Session Title: Session Ten: Psychophysics continued
Session Date: October 10
Session Time: 10:00-10:30 a.m. E.T.
Location: The Westin Southfield Hotel
Presenter: Arup Roy, Ph.D.

During his talk, Dr. Roy will discuss development and validation of novel mobility based functional vision assessment by MLYMT using longitudinal data from subjects with different levels of vision, evaluated by masked graders.

Title: Development and Validation of the Multi-Luminance Shape Discrimination Test (MLSDT) for Assessment of Near Object Recognition in Profoundly Vision Impaired Patients

Session Title: Group “A” Poster Presenters
Session Date: October 9
Session Time: 6:00-7:00 p.m. E.T.
Location: The Westin Southfield Hotel
Presenter: Michael Carlson
During his poster presentation, Mr. Carlson will discuss development and validation of novel near-object functional vision assessment by MLSDT using data from subjects with different levels of vision collected at multiple time points. 

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

On October 10, 2023   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.